Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending July 21, 2017. The document serves as a transaction notification regarding a specific insider transaction rather than a comprehensive financial report.
Key Financial Metrics
The filing does not provide aggregate financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details a specific securities transaction involving American Depositary Shares (ADSs).
- Instrument: American Depositary Shares (ADSs), ISIN: US37733W1053
- Transaction Type: Acquisition of ADSs via dividend reinvestment
- Transaction Date: July 20, 2017
- Exchange: New York Stock Exchange (XNYS)
- Price: $42.8125 per ADS
- Total Volume: 47.644 ADSs
Material Changes
The filing does not report material changes to the company's financial position or operations compared to prior periods. It reports a routine transaction under the Deferred Annual Bonus Plan Post-Tax.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. The transaction was executed by Mr. B McNamara, CEO of Consumer Healthcare, following the reinvestment of dividends paid on July 13, 2017.
Investor Verification Checklist
- Verify the identity of the Person Discharging Managerial Responsibilities (PDMR) as Mr. B McNamara.
- Confirm the transaction was an acquisition via dividend reinvestment, not an open-market purchase.
- Note that this filing does not contain quarterly or annual financial performance data.
- Check the specific ISIN (US37733W1053) for the ADSs involved.